282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancer
Oliver Klein(Olivia Newton-John Cancer Wellness & Research Centre), A. Nagrial(Westmead Hospital), Rosemary Harrup(University of Tasmania), Michelle Brown(Moderna Therapeutics (United States)), Robert Zielinski, Ashray Gunjur(Wellcome Sanger Institute), Dafydd G. Thomas(University of Manchester), Damien Kee(Peter MacCallum Cancer Centre), Jonathan Cebon(La Trobe University), Ian Collins(St. James's Hospital), W-S. Lam(Fiona Stanley Hospital), Henry Chan(Calvary Mater Newcastle Hospital), M. Michael(Peter MacCallum Cancer Centre), Jamie Palmer(Olivia Newton-John Cancer Wellness & Research Centre), S.J. Harris(Bendigo Health), Jimmy Bok Yan So(National University of Singapore), Matteo S. Carlino(The University of Sydney), Craig Underhill(AstraZeneca (United Kingdom)), Ken Wilkie(Olivia Newton-John Cancer Wellness & Research Centre), J. Torres(Goulburn Valley Health)
Cited by 3
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k